The Durham, North Carolina-based startup's platform uses an image-based, tissue box-sized tool that cultures cells to capture long-term phenotypic behavior.
An analysis of naturally occurring alleles in the lipoprotein lipase pathway found that they and LDL-C-linked alleles affect disease risk independently.
The planned program is part of beta test of Repositive’s Cancer Models platform which connects biopharmaceutical companies and contract research organizations.
The firm will use the funds to advance its high-throughput single-cell analysis platform to analyze heterogeneity in cell populations for research and drug discovery.
UMich's Arul Chinnaiyan plans to use the funding to develop new tools and technologies to identify biomarkers for cancer diagnosis and treatment.
The collaboration will involve Evotec's Panomics platform, which integrates the analysis of genomic, transcriptomic, and proteomic data.
After a series of duplication and rearrangement events, the genes involved in two key pathways producing morphine, codeine, and noscapine have clustered in the genome.
Vertex Pharmaceuticals has invested £10.5 million in the British analytics company as the companies launch a multiyear R&D partnership seeking novel drug targets.
The companies will combine their respective technologies to create a platform for discovering and developing drugs for certain genetic diseases.
Investigators from the school will use the funding to continue a research program applying genomics to hearing loss screening and treatment.
The company uses genome editing technologies for agricultural and biomedical applications, including therapeutic cell, tissue, and organ generation.
Researchers used CRISPR to engineer mice that have multiple genetic variants associated with late-onset AD to facilitate research into biomarkers and treatments.
With a $300 million investment in 23andMe, GSK pivots toward personalized medicine again, while the consumer genomics firm hitches its drug development ambitions to GSK.
The companies will initially contribute equally to funding the collaboration and will share in future proceeds from drugs developed within the partnership.
Strata will refer individuals with HER-2 mutations identified through its screening trial for consideration as subjects in Puma's SUMMIT trial.
Under the new collaboration, Predicine will use its GeneRADAR technology to aid Kintor in the development and advancement of novel drugs.
The partners have been working together since 2013 to use cancer and cardiovascular genomics for drug discovery.
The companies have launched a center that offers consulting and management specifically for genomically targeted or precision medicine trials.
The companies are creating a new center that will offer support services to biopharmaceutical companies, CROs, and others in designing genetically informed clinical trials.
The firm has developed a new classifier for bladder cancer and continues to work with pharma companies in the lung cancer space.
Senator Lamar Alexander (R-Tenn.), who chairs the Senate health committee, will be retiring at the end of his term, Stat News reports.
UCSF researchers find that having two X chromosomes may contribute to women's longer lifespans, according to Discover's D-brief blog.
The Wall Street Journal reports on the US Centers for Disease Control and Prevention's use of genetic approaches to study foodborne illnesses.
In PNAS this week: immune cell profiling of wild baboons by social status, metabolomics profiling of esophageal tumors, and more.